Schnellzugriff

  • Über uns

    Lernen Sie Fresenius Kabi, unsere wichtigsten Kennzahlen, unsere Ziele und weitere Komponenten der Fresenius-Gruppe kennen.

  • Portfolio

    Entdecken Sie das Portfolio von Fresenius Kabi in den Bereichen Pharma, Ernährung, Medizintechnik und Biopharmazie. Erforschen Sie unsere innovativen Lösungen für verbesserte Gesundheitsergebnisse

  • Offene Stellen

    Erkundigen Sie sich über unsere aktuellen Karrieremöglichkeiten

Michael Mayr takes over expanded role as Managing Director Austria & Switzerland

Press Release

1 Juli 2025
  • Starting from July 1st 2025, Michael Mayr will be responsible for the market activities of Switzerland, in an expanded role as Managing Director Austria & Switzerland
  • Michael Mayr has gained more than 20 years of experience in the pharmaceutical industry, having held diverse leadership roles at national and international level
  • Michael has been General Manager of Fresenius Kabi Austria since 2022, where he is responsible for the marketing & commercial activities of Fresenius Kabi in Austria.

Michael Mayr is appointed Managing Director Austria & Switzerland, for the global healthcare company Fresenius Kabi, an operating company of the Fresenius Group, with an expansive product portfolio providing access to high-quality and lifesaving medicines and technologies such as generic intravenous drugs, clinical nutrition, biosimilars and medical technologies. Michael takes over this position in Switzerland from Matteo Boggi, who successfully led Switzerland since 2023 and who now joins Fresenius Kabi Spain as Managing Director Iberia.

An Austrian national, Michael Mayr joined Fresenius Kabi in 2021. He brings with him more than 20 years of experience in the pharmaceutical, over the counter, medical devices and medical nutrition sectors. Prior to his time at Fresenius Kabi, he held leadership roles in companies like such as Sandoz and the Austrian Richter Pharma.

Throughout his career, Michael has built a solid experience in driving sustainable business growth and shaping and executing customer-focused marketing and commercial strategies.

“I am delighted to announce Michael Mayr's expanded role as Managing Director Austria & Switzerland. Throughout his career, Michael has consistently demonstrated a positive mindset and a willingness to embrace new challenges. Managing two distinct markets, each with its unique business dynamics, will be one of Michael's upcoming new challenges. His extensive experience and unwavering commitment to excellence will undoubtedly drive our business forward in both Austria and Switzerland.

I would like to express my gratitude to Matteo Boggi for his valuable contribution which has been instrumental in achieving good results in Switzerland.”

Marc Crouton, Member of Fresenius Kabi Management Board, President of Fresenius Kabi Region Europe

Marc Crouton

“I am honored to take on this expanded role and look forward to continuing our Fresenius Kabi growth journey in both Austria and Switzerland. Together with our dedicated teams, we will strengthen our commitment to delivering innovative and reliable healthcare solutions that make a meaningful difference in patients’ lives."


Michael Mayr, Managing Director Austria & Switzerland

Marc Crouton
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies.


In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care.

Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. In line with the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare.

Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale.
For more information, please visit www.fresenius-kabi.com
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release.
Management Board: Pierluigi Antonelli (Chairman), Marc Crouton, Andreas Duenkel, Dr. Christian Hauer,
Dr. Marc-Alexander Mahl, Dr. Sang-Jin PakChairman of the Supervisory Board: Wolfgang KirschRegistered Office: Bad Homburg, GermanyCommercial Register: Amtsgericht Bad Homburg - HRB 11654